iCAD To Showcase PowerLook Tomo Detection Technology At SBI/ACR Breast Imaging Symposium

NASHUA, N.H. and LOS ANGELES, April 6, 2017 /PRNewswire/ -- (Booth #300) – iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the Company will highlight PowerLook® Tomo Detection, an innovative, concurrent-read computer aided detection solution for digital breast tomosynthesis that can save radiologists valuable reading time without compromising clinical performance, at its booth #300 at the SBI/ACR Breast Imaging Symposium from April 6-9, 2017 in Los Angeles, California. PowerLook Tomo Detection received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) on March 24, 2017 and is the latest innovation available on the PowerLook® Breast Health Solutions platform. 

"Following the recent approval from the FDA, our team is well positioned to bring this innovative cancer detection solution to radiologists across the country, helping them optimize productivity and efficiency without compromising reader performance," said Ken Ferry, CEO of iCAD. "PowerLook Tomo Detection is built on the latest deep learning technology that enables the solution to achieve very high detection accuracy."

In each exam, 2D digital mammography typically produces four images while digital breast 3D tomosynthesis (DBT) can produce hundreds. With DBT, radiologists must spend significantly more time to review and interpret each exam. PowerLook Tomo Detection automatically analyzes each tomosynthesis plane, helping radiologists identify suspicious areas with greater speed and precision. The suspicious areas identified by PowerLook Tomo Detection are blended onto a 2D synthetic image, creating a single enhanced image. The process allows radiologists to navigate the large tomosynthesis data set more efficiently. 

"Since we launched PowerLook Tomo Detection in the E.U. in April 2016, multiple high-volume medical facilities have adopted the technology," added Ferry. "Following our FDA approval, we anticipate that many leading healthcare facilities in the U.S. will also recognize the clinical and patient benefits our technology offers. We believe this technology will establish a new standard for how computers and artificial intelligence assist radiologists in detecting breast cancer." 

PowerLook Tomo Detection is currently approved for use with GE Healthcare's digital breast tomosynthesis.  The full suite of PowerLook Breast Health Solutions will be on display during the SBI/ACR Breast Imaging Symposium. Additional information is available at www.icadmed.com. 

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. For more information, visit www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "would", "could", "consider", "project", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

Contact:

For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030
www.theruthgroup.com
[email protected]

or

For iCAD media inquiries:

Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
[email protected]

SOURCE iCAD

Related Links

http://www.icadmed.com